Xenon Pharmaceuticals Inc.

3 days ago · proactiveinvestors.com

Xenon Pharmaceuticals Inc. (XENE:NASDAQ) shares were down 30%, on Friday morning after the company voluntarily halted new enrollment in major depressive disorder and bipolar depression studies. The events were consistent with azetukalner's known safety profile, Xenon said, but had not appeared in the earlier phase II X-NOVA depression trial.

3 days ago · zacks.com

Xenon files an FDA application for azetukalner in epilepsy as its depression studies face a temporary enrollment pause.

3 days ago · benzinga.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) submitted a New Drug Application to the U.S. Food and Drug Administration for its investigational drug azetukalner to treat focal seizures.

3 days ago · schaeffersresearch.com

Stock futures are mixed after last session's rebound, with several Fed officials scheduled to make remarks

3 days ago · barrons.com

Xenon Pharmaceuticals says it paused trials for azetukalner in major depressive disorder and bipolar depression following ‘adverse events.'

3 days ago · seekingalpha.com

Xenon Pharmaceuticals Inc. (XENE) Discusses Azetukalner NDA Submission for Focal Seizures and Psychiatry Program Update Transcript

3 days ago · reuters.com

Xenon Pharmaceuticals on Thursday said it has temporarily paused enrolling new patients in ​clinical studies testing its experimental drug for ‌major depression and bipolar disorder, following reports of mental and nervous system-related side effects.

4 days ago · globenewswire.com

VANCOUVER, BC and BOSTON, MA, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced it has submitted a New Drug Application (NDA) for azetukalner in focal seizures (FS) to the U.S. Food and Drug Administration (FDA).

18 days ago · globenewswire.com

VANCOUVER, BC and BOSTON, MA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at an upcoming investor conference:

26 days ago · globenewswire.com

VANCOUVER, BC and BOSTON, MA, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced multiple data presentations at the upcoming 16th European Epilepsy Congress (EEC), taking place September 5-9, 2026, in Athens, Greece.